IRON · Disc Medicine

The thesis

Disc Medicine's shares are modestly more likely than not to beat the S&P 500 over the next three months. Its lead drug, bitopertin, met every endpoint of the Phase 3 APOLLO trial on 19 October 2026, and that result answers the reason the Food and Drug Administration (FDA) rejected the drug in February. Two dated events settle it: pipeline data at the American Society of Hematology (ASH) meeting from 12 December 2026, and the new drug application (NDA) resubmission the company guides for the end of 2026.

The FDA issued a complete response letter (CRL) on 13 February 2026. HCPLive and PharmExec reported that the agency accepted that bitopertin lowers protoporphyrin IX (PPIX), the toxic metabolite behind erythropoietic protoporphyria (EPP), a rare disease that makes sunlight painful. It did not accept that the drop predicts clinical benefit, and it asked for data from another trial. In 183 patients, APOLLO cut PPIX by 41.4% against placebo (p<0.0001) and added 12.2 hours a month of time in light without pain (p=0.0010), according to the company's 19 October 2026 release. The company now seeks traditional approval, where the first filing sought accelerated approval, BioSpace reported on 19 October 2026.

The shares closed at $80.00 on 13 November 2026, down from $87.08 on 11 November 2026. The two lower closes spanned the company's fireside chat at the Stifel healthcare conference on 12 November 2026. The 3-month change is −0.1%: the shares stand where they stood in mid-August, after a slide to the 52-week closing low of $55.74 on 14 October 2026 and the recovery on the trial result.

The rating is Medium because the February letter's main question now has a direct answer and the company guides its cash to last into 2030. Against that, the company keeps issuing stock, insiders keep selling, and the FDA decision, guided for mid-2027, falls after the three-month window. The last close sits just above the kill line, so the coming sessions test the call directly.

Bullish and bearish views on Disc Medicine, Inc.

The bull case on Disc Medicine, Inc. (IRON), in brief: APOLLO answers the FDA's stated objection. The bear case: new shares keep coming to market.

Bull case

• APOLLO answers the FDA's stated objection. The CRL asked for proof that the PPIX drop means real benefit for patients. APOLLO showed a 12.2-hour monthly gain in pain-free time in light against placebo and met every secondary endpoint (company release, 19 October 2026).
• Funding runs into 2030. Cash, equivalents and marketable securities were $682.8 million on 30 September 2026, before the October offering. The company says that cash plus the offering's proceeds funds operations into 2030 (third-quarter report, 5 November 2026).
• Management is planning the launch. On 9 November 2026 Chief Executive Officer John Quisel said bitopertin could reach the market in 12 to 16 months. He cited about $1.1 billion of pro forma cash, an expected EPP price of about $300,000 a year and a planned 24-person sales force (Investing.com, 10 November 2026).
• Two more programs report at ASH. On 4 November 2026 the company said it would present updated selcodebart data in anemia of myelofibrosis and DISC-3405 data at ASH. Quisel said on 9 November 2026 that the selcodebart Phase 3 design will be shared there, with a pivotal trial expected to start in 2027.
• Analyst targets moved up after the report. Guggenheim started coverage with a Buy rating and a $132 target on 9 November 2026. HC Wainwright raised its target to $127 on 6 November 2026.

Bear case

• New shares keep coming to market. The company priced 6,000,000 shares at $75.00 on 21 October 2026, raising $450 million gross. On 5 November 2026 it filed an at-the-market sales agreement with TD Cowen for up to $189.93 million more, and the diluted share count was up 10.6% from a year earlier in the quarter to 30 September 2026.
• Insiders sell into strength. Chief Medical Officer William Jacob Savage sold 16,035 shares at $85.09 on 10 November 2026 under a Rule 10b5-1 plan (Form 4 filed 12 November 2026). Director Kevin Bitterman sold 41,825 shares at an average of $80.13 from 19 October to 21 October 2026, and Quisel sold 33,000 shares at an average of $79.15 on 17 August 2026 after an option exercise (SEC Form 4 filings).
• Tolerability could shape the label. Dizziness was the most common adverse event in APOLLO, reported in 50% of bitopertin patients and mostly mild or moderate, according to the company's 5 November 2026 update.
• The approval is still months away. The company guides to an FDA decision by mid-2027. Until then, any gain in the shares has to come from filing milestones and pipeline data.
• The company burns cash. Operating cash flow was −$190 million over the four quarters to 30 September 2026, and net loss was $243 million over the same period (Form 10-Q, filed 5 November 2026).

Price setup

The shares closed at $80.00 on 13 November 2026, after $83.23 on 12 November 2026 and $87.08 on 11 November 2026. As of 13 November 2026, the 50-day moving average is $71.59 and the 200-day moving average is $70.95; the last close is above both.

The 52-week closing low is $55.74, set on 14 October 2026, five sessions before the APOLLO result. The 52-week intraday high is $99.50, set on 8 December 2025, before the rejection; the last close is 19.6% below it. A move back toward that high would mean the market treats the resubmission as close to a full reversal of the February letter.

The October offering priced at $75.00, and a common market view is that a large offering's price acts as a floor for the shares. Across liquid US stocks, the standard deviation of 63-session returns was 27% in 2026, so a three-month window for a single biotech carries wide swings in either direction.

Catalysts ahead

• 12 December 2026: 68th ASH Annual Meeting (12 December to 15 December 2026): selcodebart myelofibrosis-anemia update and Phase 3 design, DISC-3405 polycythemia vera data. Shows whether the pipeline behind bitopertin holds up and when a second registration trial starts, which matters for value beyond a single EPP approval.
• ~31 December 2026 (est.): Bitopertin NDA resubmission to the FDA, guided for the end of 2026. Filing on time keeps the mid-2027 decision on track; the FDA's acknowledgment and goal date then set the review clock.
• ~31 December 2026 (est.): Selcodebart End-of-Phase 2 FDA feedback and pivotal plan for anemia of myelofibrosis. Sets whether a second program moves into a registration trial in 2027.
• ~30 June 2027 (est.): Expected FDA decision on the resubmitted bitopertin NDA (mid-2027 per company). Approval would make Disc Medicine a commercial company; a second rejection would remove most of the case.

What would change the view

A daily close below $78.47, the 5 November 2026 close on the day of the third-quarter report and the at-the-market filing, which would erase the post-report gains; or no bitopertin NDA resubmission announced by 31 December 2026.

The risks this note tracks, each with what would confirm it:

• The bitopertin resubmission slips past the guided end-2026 timing. Confirmed by: no company announcement of the NDA resubmission by 31 December 2026.
• The FDA sets a review goal later than mid-2027 or raises new questions on the resubmitted application. Confirmed by: a company disclosure of an FDA action date after 30 June 2027 or of an advisory committee meeting.
• Share sales under the TD Cowen at-the-market program dilute holders and cap rallies. Confirmed by: at-the-market proceeds or a higher share count reported in the 2026 10-K.
• Dizziness, reported in 50% of APOLLO bitopertin patients, leads to a restrictive label or weak uptake. Confirmed by: FDA labeling discussions or full APOLLO data showing discontinuations tied to dizziness.
• Pipeline data at ASH disappoint and the market reprices the non-bitopertin programs. Confirmed by: updated selcodebart or DISC-3405 data at ASH from 12 December 2026 showing weaker responses than earlier cohorts.

What it trades with

Disc Medicine's shares trade mainly on the company's own regulatory and trial dates. The 13 February 2026 rejection and the 19 October 2026 APOLLO result drove the largest moves of the past year, and the 21 October 2026 offering set the price at which new institutional holders bought.

Other rare-disease names in the same group, Viridian Therapeutics (VRDN), Xeris Biopharma (XERS), PepGen (PEPG), Liquidia (LQDA) and Eton Pharmaceuticals (ETON), depend on unrelated drugs, so their results say little about bitopertin's review. Headlines tagged with the IRON ticker about Ironveld plc, a UK-listed miner, appeared on 30 October 2026 and 5 November 2026; they concern a different company.